Suppr超能文献

COVID-19 肺癌患者住院死亡率的临床特征和危险因素:一项多中心、回顾性、队列研究。

Clinical characteristics and risk factors for in-hospital mortality of lung cancer patients with COVID-19: A multicenter, retrospective, cohort study.

机构信息

Department of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.

出版信息

Thorac Cancer. 2021 Jan;12(1):57-65. doi: 10.1111/1759-7714.13710. Epub 2020 Nov 3.

Abstract

BACKGROUND

Data on clinical, laboratory, and radiographic characteristics and risk factors for in-hospital mortality of lung cancer patients with COVID-19 are scarce. Here, we aimed to characterize the early clinical features of lung cancer patients with COVID-19 and identify risk factors associated with in-hospital mortality.

METHODS

All consecutive lung cancer patients with laboratory-confirmed COVID-19 admitted to 12 hospitals in Hubei province, China, from 3 January to 6 May 2020 were included in the study. Patients without definite clinical outcomes during the period were excluded. Data on initial clinical, laboratory and radiographic findings were compared between survivors and nonsurvivors. Univariable and multivariable logistic regression analyses were used to explore the risk factors associated with in-hospital mortality.

RESULTS

Of the 45 lung cancer patients (median [interquartile range] age, 66 [58-74] years; 68.9% males) included, 34 (75.6%) discharged and 11 (24.4%) died. Fever (73.3%) and cough (53.3%) were the dominant initial symptoms, and respiratory symptoms were common. Lung cancer patients also presented atypical appearances of COVID-19. In the multivariable analysis, prolonged prolongation prothrombin time (PT) (OR = 2.1, 95% CI: 1.00-4.41, P = 0.0497) and elevated high sensitivity cardiac troponin I (hs-TNI) (OR = 7.65, 95% CI: 1.24-47.39, P = 0.0287) were associated with an increased risk of in-hospital mortality.

CONCLUSIONS

Lung cancer patients with COVID-19 have high in-hospital mortality. Prolonged PT and elevated hs-TNI are independent risk factors for in-hospital mortality of lung cancer patients with COVID-19.

KEY POINTS

SIGNIFICANT FINDINGS OF THE STUDY: Lung cancer patients with COVID-19 have atypical early symptoms and imaging features. The prolonged prothrombin time and elevated high sensitivity cardiac troponin I are independent risk factors for in-hospital mortality of lung cancer patients with COVID-19.

WHAT THIS STUDY ADDS

This study characterizes the early clinical features of lung cancer patients with COVID-19 in China, and identifies the risk factors associated with in-hospital mortality of lung cancer patients with COVID-19.

摘要

背景

关于伴有 COVID-19 的肺癌患者的住院死亡率的临床、实验室和影像学特征以及危险因素的数据十分缺乏。在此,我们旨在描述伴有 COVID-19 的肺癌患者的早期临床特征,并确定与住院死亡率相关的危险因素。

方法

本研究纳入了 2020 年 1 月 3 日至 5 月 6 日期间来自中国湖北省的 12 家医院的所有经实验室确诊为 COVID-19 的连续肺癌患者。在此期间无明确临床结局的患者被排除在外。比较了存活者和非存活者之间的初始临床、实验室和影像学发现。采用单变量和多变量逻辑回归分析来探讨与住院死亡率相关的危险因素。

结果

在纳入的 45 例肺癌患者中(中位[四分位间距]年龄,66 [58-74]岁;68.9%为男性),34 例(75.6%)出院,11 例(24.4%)死亡。发热(73.3%)和咳嗽(53.3%)是主要的初始症状,呼吸道症状常见。肺癌患者也表现出 COVID-19 的非典型表现。在多变量分析中,延长的凝血酶原时间(PT)(比值比[OR] = 2.1,95%置信区间[CI]:1.00-4.41,P = 0.0497)和升高的高敏肌钙蛋白 I(hs-TNI)(OR = 7.65,95%CI:1.24-47.39,P = 0.0287)与住院死亡率的增加相关。

结论

伴有 COVID-19 的肺癌患者的住院死亡率较高。延长的 PT 和升高的 hs-TNI 是伴有 COVID-19 的肺癌患者住院死亡率的独立危险因素。

关键点

本研究的重要发现:伴有 COVID-19 的肺癌患者具有非典型的早期症状和影像学特征。延长的凝血酶原时间和升高的高敏肌钙蛋白 I 是伴有 COVID-19 的肺癌患者住院死亡率的独立危险因素。

本研究新增内容

本研究描述了中国伴有 COVID-19 的肺癌患者的早期临床特征,并确定了伴有 COVID-19 的肺癌患者住院死亡率的相关危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/86aa/7779192/427cc72b870d/TCA-12-57-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验